Doxorubicin-Eluting Beads

DRUG5 trials

Sponsors

National Cancer Institute (NCI), Swiss Cancer Institute, University College, London, Sohag University

Conditions

Hepatocellular CancerHepatocellular CarcinomaLiver CancerMetastatic Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma

Early Phase 1

Role of DEB-TACE Versus c-TACE in Treatment of HCC

Sohag UniversityHepatocellular Carcinoma

Start: 2022-01-01End: 2024-01-30Updated: 2023-04-12

Phase 1

Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

TerminatedNCT01009801

Swiss Cancer InstituteLiver Cancer

Start: 2010-02-28End: 2015-06-30Updated: 2015-07-07

Phase 2

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Active, not recruitingNCT03937830

National Cancer Institute (NCI)Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma

Start: 2021-03-10End: 2027-12-31Updated: 2026-09-08

Phase 3

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

CompletedNCT01004978

National Cancer Institute (NCI)Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma

Start: 2009-10-28End: 2022-12-21Updated: 2024-01-03

Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

University College, LondonLiver Cancer

Start: 2010-11-30Target: 412Updated: 2011-05-13

Related Papers

Combined treatment of durvalumab, bevacizumab and tremelimumab in subjects with hepatocellular carcinoma (HCC) or biliary tract carcinoma (BTC).

Journal of Clinical Oncology2025-05-28

472 Anti-VEGF treatment amplifies immune checkpoint inhibitor induced immune responses by targeting B and regulatory T cells

Regular and Young Investigator Award Abstracts2023-10-311 citations

A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.

Journal of Clinical Oncology2023-06-01

419 Combined anti-VEGF, anti-CTLA4 and anti-PDL1 treatment induces strong immune responses in patients with cholangiocarcinoma: results from a clinical trial/in depth correlative studies and mouse studies

Regular and Young Investigator Award Abstracts2022-11-012 citations